» Articles » PMID: 20374225

Self-reported Antenatal Adherence to Medical Treatment Among Pregnant Women with Crohn's Disease

Overview
Date 2010 Apr 9
PMID 20374225
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adherence to medical treatment among women with Crohn's disease (CD) prior to and during pregnancy has never been reported.

Aim: To examine both the predictors and prevalence rates of non-adherence to maintenance medical treatment among women with CD prior to and during pregnancy.

Methods: Among a population of 1.6 million inhabitants, we identified a total of 132 women with CD who had given birth during 2000-2005. Questionnaires were used to investigate predictors and extent of adherence. The validity of self-reported use of medication was assessed using data from the Danish Prescription Database. We used logistic regression to estimate prevalence odds ratios for non-adherence according to smoking status and other predictors.

Results: Eighty percent of the patients returned the questionnaire. A total of 58 (54%) women reported to have been on medical treatment, 50 of whom had fulfilled a prescription on relevant medication. Adherence to medical treatment was 72%. Fear of a negative effect on fertility/foetus was a reason for non-adherence by 18.8% prior to, and by 45.5% during, pregnancy. Among smokers, 30.8% were non-adherent compared with 11.5% among nonsmokers (prevalence odds ratio 3.41, 95% CI 0.8-14.7).

Conclusions: Despite fear of a negative effect on fertility/foetus, adherence to medical treatment is high in women with CD. There is no substantial variation in adherence prior to and during pregnancy. Smoking prior to pregnancy is a predictor of non-adherence.

Citing Articles

Planning to conceive within a year is associated with better pregnancy-specific disease-related patient knowledge and better medication adherence in women of childbearing age with inflammatory bowel disease.

Selinger C, Laube R, Steed H, Brookes M, BioResource N, Leong R Therap Adv Gastroenterol. 2023; 16:17562848231193211.

PMID: 37667806 PMC: 10475232. DOI: 10.1177/17562848231193211.


Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis.

Wang H, Hu Y, Chen F, Shen M BMC Pregnancy Childbirth. 2022; 22(1):854.

PMID: 36402978 PMC: 9675210. DOI: 10.1186/s12884-022-05191-z.


Positive Predictive Value of Diagnostic Codes for Inflammatory Bowel Disease in the Danish National Patient Registry Among Individuals 50+ Years, Using Patient Records as Reference Standard.

Rye C, Rubin K, Moller F, Julsgaard M, Jess T, Andersen V Clin Epidemiol. 2021; 13:335-344.

PMID: 34079376 PMC: 8164354. DOI: 10.2147/CLEP.S298770.


Review of pregnancy in Crohn's disease and ulcerative colitis.

Laube R, Paramsothy S, Leong R Therap Adv Gastroenterol. 2021; 14:17562848211016242.

PMID: 34046084 PMC: 8135214. DOI: 10.1177/17562848211016242.


Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months.

Wen T, Faye A, Lee K, Friedman A, Wright J, Lebwohl B Dig Dis Sci. 2021; 67(9):4278-4286.

PMID: 33932199 DOI: 10.1007/s10620-021-06999-z.